Kristiaan Nackaerts
A5039079234- Occupational and environmental lung diseases
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Pleural and Pulmonary Diseases
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Advanced Chemical Sensor Technologies
- Medical Imaging Techniques and Applications
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neuroblastoma Research and Treatments
- Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Radiation Dose and Imaging
- Smoking Behavior and Cessation
- Cancer Genomics and Diagnostics
- Advanced Radiotherapy Techniques
- Cancer therapeutics and mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Global Cancer Incidence and Screening
- RNA modifications and cancer
- Radiopharmaceutical Chemistry and Applications
- Biosensors and Analytical Detection
KU Leuven
2016-2025
Maastricht University
2022-2024
University Medical Center Groningen
2024
Radboud University Medical Center
2024
University of Groningen
2024
Radboud University Nijmegen
2024
University Medical Center Utrecht
2024
Utrecht University
2024
Universitair Ziekenhuis Leuven
2010-2023
Universitätsklinikum Aachen
2022
There are limited data from randomized trials regarding whether volume-based, low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among male former and current smokers.
The use of multidetector computed tomography (CT) in lung-cancer screening trials involving subjects with an increased risk lung cancer has highlighted the problem for clinician deciding on best course action when noncalcified pulmonary nodules are detected by CT.A total 7557 participants underwent CT years 1, 2, and 4 a randomized trial screening. We used software to evaluate nodule according its volume or volume-doubling time. Growth was defined as increase at least 25% between two scans....
A method to obtain the optimal selection criteria, taking into account available resources and capacity impact on power, is presented for Dutch-Belgian randomised lung cancer screening trial (NELSON). NELSON investigates whether 16-detector multi-slice computed tomography will decrease mortality compared no screening. questionnaire was sent 335,441 (mainly) men, aged 50-75. Smoking exposure (years smoked, cigarettes/day, years quit) determined, expected estimated different scenarios 106,931...
Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) phase trials. This III trial compared the safety efficacy of amrubicin versus topotecan as second-line treatment for SCLC.A total 637 patients with refractory or sensitive SCLC were randomly assigned at ratio 2:1 to 21-day cycles 40 mg/m(2) intravenously (IV) on days 1 3 1.5 IV 5. Primary end point was overall survival (OS); secondary points included...
<h3>Background</h3> In the USA annual lung cancer screening is recommended. However, optimal strategy (eg, interval, rounds) unknown. This study provides results of fourth round after a 2.5-year interval in Dutch-Belgian Lung Cancer Screening trial (NELSON). <h3>Methods</h3> Europe9s largest, sufficiently powered randomised was designed to determine whether low-dose CT reduces mortality by ≥25% compared with no 10 years follow-up. The arm (n=7915) received at baseline, 1 year, 2 and 2.5...
The NELSON (Nederlands Leuvens Longkanker Screenings Onderzoek) trial is, with 15,822 participants, the largest European lung cancer computer tomography screening trial. A volumetry-based strategy, stringent criteria for a positive screening, and an increasing length of interval are particular features trial.To determine effect referral on characteristics screen-detected cancers, to compare this across rounds, between sexes, other trials.All participants in first three rounds were included....
Several medical associations recommended lung cancer screening by low-dose computed tomography scanning for high-risk groups. Counselling of the candidates on potential harms and benefits their risk is a prerequisite screening. In NELSON trial, screenings are considered positive (part) solid nodules with volume >500 mm3 or nonsolid volume-doubling time <400 days. For this study, performance strategy in three rounds was evaluated calculations were made follow-up period 5.5 years. 458 (6%)...
IntroductionDLL3, an atypical Notch ligand, is expressed in SCLC tumors but not detectable normal adult tissues. Rovalpituzumab tesirine (Rova-T) antibody-drug conjugate containing a DLL3-targeting antibody tethered to cytotoxic agent pyrrolobenzodiazepine by means of protease-cleavable linker. The efficacy and safety Rova-T compared with topotecan as second-line therapy patients expressing high levels DLL3 (DLL3-high) was evaluated.MethodsThe TAHOE study open-label, two-to-one randomized,...